Gemfibrozil as a lipid lowering compound in hyperlipoproteinaemia. A placebo-controlled cross-over trial.
The efficacy of gemfibrozil in lowering increased serum lipoprotein concentrations was tested in a placebo-controlled cross-over trial on 30 patients. Administered in a dose of 1200 mg daily, gemfibrozil reduced increased serum triglyceride levels by approximately 50% and reduced increased serum cholesterol concentrations by about 20%. Elevated VLDL triglyceride levels were reduced by 60%, and increased LDL cholesterol concentrations were reduced by approximately 20%. The mean HDL cholesterol concentration increased during gemfibrozil treatment. No adverse reactions attributable to gemfibrozil were recorded during the trial.
D000273:Adipose Tissue / Q000201:enzymology; D000328:Adult; D000368:Aged; D001835:Body Weight; D002986:Clinical Trials as Topic; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008071:Lipoprotein Lipase / Q000378:metabolism; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014992:Xylenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000960:Hypolipidemic Agents; D007328:Insulin; D008074:Lipoproteins; D010919:Placebos; D014280:Triglycerides; D014631:Valerates; D014992:Xylenes; D005340:Fibrinogen; D008071:Lipoprotein Lipase